Navigation Links
Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
Date:4/20/2012

SEATTLE, April 20, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results and recent accomplishments for the first quarter of 2012.

First Quarter Financial ResultsFor the quarter ended March 31, 2012, total operating expenses were $18.1 million compared to $20.1 million for the same period in 2011. Net loss attributable to common shareholders decreased 66% to $17.4 million ($0.09 per share) for the quarter ended March 31, 2012 compared to a net loss attributable to common shareholders of $51.0 million ($0.35 per share) for the same period in 2011. The decrease in net loss attributable to CTI's common shareholders is primarily due to a decrease in deemed dividends and total operating expenses. CTI had approximately $27.4 million in cash and cash equivalents as of March 31, 2012.

Recent Highlights

  • In February 2012, the European Medicines Agency's ("EMA") Committee for Medicinal Products for Human Use ("CHMP") granted a positive opinion for conditional approval of CTI's MAA for Pixuvri as monotherapy for the treatment of adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma ("NHL").
  • In April 2012, CTI entered into an agreement to acquire a highly selective JAK2 inhibitor, pacritinib, which is a phase 3 candidate for treating patients with myelofibrosis ("MF").

    • "With potential approval of our MAA for Pixuvri in the E.U. to treat adult patients with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma and tosedostat gearing up to initiate a pivotal phase 3 trial in relapsed or refractory acute myeloid leukemia/myelodysplastic syndromes ("MDS") later this year, the agreement to acquire pacritinib, a highly selective JAK2 inhibitor, rounds out our novel late stage oncology drug portfolio placing us in a select group of biotech companies.  Our oncology drug portfolio now spans across
    '/>"/>

    SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... and TEL AVIV, Israel , May 24, ... "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, ... President and Chief Executive Officer, and Craig Shore ... the Benchmark Company, LLC One-on-One Investor Conference on Thursday May ... Milwaukee, WI. The format ...
    (Date:5/24/2013)... Dallas, Texas (PRWEB) May 24, 2013 ... web-based benchmarking survey on kinase profiling carried out ... data, details of the breakdown of the responses ... for the future (2015). It also highlights some ... Research survey groupings. Two bottom-up models were developed ...
    (Date:5/24/2013)... 24, 2013 The Oklahoma tornado ... its ravage, the mayor of Moore, one of the heavily ... said a report from cnn.com. Reaching out to also be ... Molderizer and Safe Shield to counter the looming mold problem. ... on May 22, 2013, caused 24 deaths, My Cleaning Products ...
    (Date:5/24/2013)... Quincy Bioscience, a leading research ... calcium-binding proteins to support healthy living, is pleased ... of apoaequorin in Food and Chemical ... British Industrial Biological Research Association. , The ... adverse effects, if any, of apoaequorin, in rats ...
    Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 2Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 3Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com 4Mayor of Oklahoma-Tornado-Impaired Town Proposes Storm Shelter Bill, My Cleaning Products Offers Complimentary Molderizer and Safe Shield to Help Victim with Looming Mold 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
    ... Bulletin Board: TBIO) today announced that it has ... (SBIR) award by the National Science,Foundation (NSF) to ... Libraries (SEAL) technology. A cost-effective and,high throughput enabling ... variations between a reference genome and a test ...
    ... Nov. 20 WWMR, Inc., the marketing research,leader ... "Most Appreciated Pain,Drug Company Survey". The top ... Endo Pharmaceuticals, according to the 100 pain clinic,physicians ... most noted for,their knowledgeable, respectful and informed sales ...
    ... (OTC Bulletin Board: DSKA) will host a teleconference call ... programs and financial results,for the third quarter of 2008. ... host the call and there will be a question-and-answer ... To participate in the teleconference, please call toll-free 800.895.0198,(direct ...
    Cached Biology Technology:Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 2Transgenomic Awarded SBIR Grant to Support Development of SURVEYOR(R) Endonuclease Adaptor-ligated Libraries (SEAL) for Determining Whole Genome Sequence Variation 3WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals 2WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals 3Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 2Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 3Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 4Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 5Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 6Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results 7
    (Date:5/22/2013)... have developed a novel technique that can detect molecular ... that is one of the most important, though time-consuming, ... a paper in Nature , post-doctoral researcher David ... Schnell of the Center for Free-Electron Laser Science (CFEL) ... finely-tuned microwave fields to identify molecular variants apart, and ...
    (Date:5/22/2013)... engineering drastically reduces the time and effort needed ... of biotechnology, scientists are reporting. Published in the ... paves the way for more rapid development of ... other activities. , Keith Shearwin and colleagues explain ... genetic material DNA into a bacterium,s genome is ...
    (Date:5/22/2013)... pneumophila bacteria is responsible for legionellosis, an infectious ... infect us, this pathogen has developed a complex method ... our cells, thus avoiding these acting against the infectious ... centre, CIC bioGUNE, in which teams from the National ... National Supercomputation Centre in Barcelona (BSC) have also participated, ...
    Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Mechanism discovered which aids Legionella to camouflage itself in the organism 2
    ... a Pew Scholar in Biomedical Sciences by the Pew ... over four years. ... performance during education and training and demonstration of outstanding ... The Pew Charitable Trusts seek particularly creative and innovative ...
    ... German . Because of its toxicity ... CCl4) can no longer be used or produced in many ... chlorinated hydrocarbons, such as chloroform (trichloromethane, CHCl3), also produce CCl4 ... rid of this unwanted substance? A team headed by Bert ...
    ... major initiative to create alternative nesting sites for the largest colony ... juvenile salmon and steelhead in the Columbia River is finding ... at Crump Lake in southern Oregon, which was just constructed in ... 135 nesting pairs of Caspian terns, as well as more than ...
    Cached Biology News:Julia Zeitlinger named Pew Scholar 2Fair trade 2Project succeeding to relocate Caspian terns 2Project succeeding to relocate Caspian terns 3Project succeeding to relocate Caspian terns 4Project succeeding to relocate Caspian terns 5Project succeeding to relocate Caspian terns 6
    EnzChek cellulase substrate *blue fluorescent, 339/452...
    ... Kb RNA Ladder is suitable for sizing single-stranded RNA ... or formaldehyde agarose gels. The ladder consists of nine ... 4 6 8 and 10 kb) to simplify size ... the other bands allowing easy orientation and identification of ...
    ...
    One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
    Biology Products: